)
Laura Faravelli
VP Business Development
Newron Pharmaceuticals SpA
Laura Faravelli is Vice President of Business Development at Newron Pharmaceuticals, bringing over 20 years of experience in CNS drug development spanning research, regulatory approval, and business opportunity analyses. Appointed VP in July 2023, she combines deep scientific expertise with strategic business leadership.
Laura has been instrumental in securing key strategic licensing partnerships, including agreements with EA Pharma (an Eisai subsidiary) in 2024 and Myung In in 2025, significantly advancing Newron’s growth strategy and supporting the development and global positioning of evenamide for schizophrenia through critical stages.
Previously, Laura contributed to the successful development and approval of CNS therapies, including safinamide (Xadago®), which received marketing authorization from both the EMA and FDA. She holds a PhD in Neurobiology with additional training in Regulatory Affairs and Market Access, enabling her to bridge science and business effectively.
Sessions
-
24-Jun-2026Theater 4Newron Pharmaceuticals SpA
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}